CD40 ligand is a proinflammatory cytokine released into the circulation mainly by activated platelet but also by endothelial cells, smooth muscle cells, macrophages, or T-lymphocytes. Unrelated as it seems to most of the traditional atherosclerotic risk factors or to subclinical atherosclerosis, 1 soluble CD40 ligand (sCD40L) has been independently associated with an increased risk of coronary and cerebrovascular events, performing better as a marker of plaque vulnerability than of plaque burden. Adjusted for potential confounders, this relative risk varied between 1.9 and 2.8 (ref. 2).
Background
Elevated levels of the proinflammatory cytokine soluble CD40 ligand (sCD40L) were reported in subjects with diabetes, impaired glucose tolerance, metabolic syndrome (Ms), obesity, and insulin resistance. Metabolic abnormalities might also account for increased sCD40L in subjects with essential hypertension.
Methods several metabolic and vascular correlates of sCD40L levels have been investigated in 90 nondiabetic never-treated essential hypertensive men. results Median sCD40L level was 8.7 ng/ml (interquartile range: 4.9-11.7). On the basis of sCD40L, subjects were divided by tertiles (thresholds at 6.6 and 11.0 ng/ml). the three groups did not differ for age, body mass index (BMI), smokers, blood pressure (Bp), prevalence of nondippers, lipids and lipoproteins, renal function, and albuminuria. Carotid intima-media thickness (IMt: 0.79 ± 0.22, 0.83 ± 0.29, and 0.85 ± 0.30 mm) and percentage of subjects with wall thickening (IMt >0.9 to <1.3 mm: 23, 27, and 27%, respectively) were superimposable in the three groups. No differences were observed in high-sensitivity C-reactive protein (hs-CRp) and no correlation emerged between sCD40L and hs-CRp. An increase through sCD40L tertiles emerged for basal insulin (11.2 ± 5.6, 14.7 ± 7.7, and 16.8 ± 13.5 µU/ml, P = 0.10) and fasting glucose (95 ± 11, 103 ± 16, and 105 ± 14 mg/dl, P = 0.028). Consistently, along with the increase in sCD40L, a worsening in insulin sensitivity was observed, which was expressed as homeostasis model assessment for insulin sensitivity (HOMA%s: 99 ± 52, 77 ± 43, and 72 ± 35, P < 0.05), composite insulin sensitivity index (IsIcomp; Matsuda index: 5.11 ± 2.65, 3.61 ± 1.98, and 3.28 ± 1.87, P = 0.025), or oral glucose insulin sensitivity (OGIs) index (OGIs: 421 ± 67, 386 ± 90, and 362 ± 72, P = 0.004).
conclusions
In newly diagnosed hypertensive men, sCD40L levels are inversely related to insulin sensitivity, with no correlation with Bp, other cardiovascular risk factors, or the degree of subclinical atherosclerosis. articles sCD40L in Hypertension a group of never-treated nondiabetic hypertensive patients. High-sensitivity C-reactive protein (hs-CRP) was also measured as a potential inflammatory determinant of platelet activation and sCD40L release. 18 
Methods
Patients. Data refer to 90 never-treated Caucasian hypertensive men (aged 25-66) recruited in the context of a preventive program offered to never-treated subjects referred by general practitioners. Patients were considered hypertensive when systolic and/or diastolic blood pressure (BP) calculated as the mean of two measurements obtained by mercury sphygmomanometer after 10-min resting and performed twice at 1-week interval were concordant for exceeding 140 and/or 90 mm Hg. Inclusion criteria were: absence of diabetes, body mass index (BMI) <35 kg/m 2 , normal or mildly decreased renal function (estimated glomerular filtration rate (eGFR) >60 ml/min/1.73 m 2 ), no proteinuria (albumin excretion rate (AER) <200 µg/min), and no concomitant use of any kind of medications including antiplatelet and nonsteroidal antiinflammatory drugs.
Current smokers, class 2 or higher obese subjects, and those with a history of cardiovascular disease were excluded. None had evidence of atherosclerotic disease as assessed by carotid ultrasonography, evidence or history of heart failure, and/or left ventricular dysfunction, atrial fibrillation, and significant valvular defect. None had a family history of premature cardiovascular disease. Anthropometric measures-height, weight (BMI as weight/height 2 (kg/m 2 )), and waist circumferencewere taken by standard procedures while subjects wore indoor clothes without shoes.
All eligible subjects were requested to enter the study and all patients providing written informed consent were recruited. Therefore, we are confident that this sample is indeed representative of the population of newly diagnosed hypertensive men attending on an outpatient basis. The study was carried out in accordance with the Declaration of Helsinki and approved by the institutional review board. Experimental evaluations were completed in a 2-week period.
Sampling and laboratory procedures. To assess AER, three overnight urine collections were obtained on 3 consecutive days. Blood sample was drawn the third morning at fasting. For plasma sampling, blood was drawn into prechilled EDTA pyrogen-free tubes immediately immersed in melting ice. To avoid platelet activation during postharvesting procedure, platelet-free plasma for sCD40L analysis was carefully prepared by sample centrifugation at 3,000 rpm for 10 min.
A standard 75-g oral glucose tolerance test (OGTT) was performed (sampling schedule after baseline, at 30, 60, 90, and 120 min) to define glucose tolerance 19 Serum cystatin-C was measured by a particle-enhanced nephelometric immunoassay (N Latex Cystatin C; Dade Behring, Marburg, Germany).
Plasma sCD40L was determined by enzyme-linked immunoadsorbent assay (R&D Systems, Minneapolis, MN); CRP was measured by a highly sensitive (to 0.3 mg/l) immunoassay (N High Sensitivity CRP; Dade Behring, Marburg, Germany). For both analytes, inter-and intra-assay variations were <8%. Albumin in urine was assayed using a Behring Nephelometer II analyzer (Dade Behring, Milton Keines, UK), which detects albumin down to 0.12 mg/dl. Microalbuminuria was defined as an AER of 20-200 µg/min.
Ambulatory BP monitoring. Twenty-four-hour BP was measured by validated oscillometric monitor (Diasys Integra; Novacor, Rueil-Malmaison Cedex, France) on a regular working day. The recording began between 8.30 and 9.00 am with readings at 15-min intervals until midnight, and at 30-min intervals from midnight to 8.00 am with at least 90% valid measurements. Patients were instructed to record their activity as well the occurrence of poor sleep. Dipping was defined as the >10% reduction of both systolic and diastolic night-time BP compared with daytime values.
Carotid ultrasonography. Carotid scans were obtained using a high-resolution B-mode ultrasound imaging system equipped with a 7.5-12 MHz transducer (MyLab25; ESAOTE, Florence, Italy). Carotid intima-media thickness (IMT) was measured in the far wall of the common carotid artery, 1 cm proximal to the carotid bulb, by a real-time computerized edge detection system. The IMT was defined as the distance (mean of six measurements to estimate the overall IMT) from the leading edge of the lumen-intima interface to the leading edge of the mediaadventitia interface of the far wall. Coefficient of variation for repeated carotid IMT measurements was 2%. Wall was considered normal when IMT was <0.9 mm and thickened when IMT was ≥0.9 to <1.3 mm. Subjects with an IMT ≥1.3 mm were excluded. Calculations. Plasma glucose response and total insulin secretion obtained by OGTT were evaluated from the area under the curve for plasma glucose and insulin calculated from fasting, 30-, 60-, 90-, and 120-min plasma concentrations using the trapezoid rule. β-Cell function (%B) and insulin sensitivity (%S) were evaluated from pairs of fasting glucose and insulin measurements (homeostasis model assessment, HOMA). 21 Furthermore, both ISIcomp (Matsuda index) and oral glucose insulin sensitivity (OGIS) index, which take into account mean and, respectively, punctual glucose and insulin values throughout the OGTT, were calculated. 22 Finally, the MFFM index, a predictor of glucose disposal rates (M) corrected for fat-free mass (FFM) developed from hyperinsulinemic-euglycemic clamp was calculated as a weighted combination of log-transformed fasting insulin Statistics. Sample size was calculated against HOMA%S for analysis of variance comparison. With an anticipated withingroup s.d. for HOMA%S (assumed as homogeneous between groups) of 25% and an anticipated minimal detectable difference among sCD40L tertiles of 20%, 27 cases per group were required for a two-tailed α of 0.05 and a 10% risk of type 2 error. Descriptive statistics were mean ± s.d. or median and interquartile range for skewed data. The data were analyzed by parametric (Student's unpaired t-test or one-way analysis of variance) or nonparametric (Mann-Whitney U-test or Kruskal-Wallis) methods according to variable distribution. Percentages describe categorical variables (Fisher's exact test or χ 2 -test). Linear associations were assessed by Spearman rank correlation, while multiple stepwise regression analysis was employed to assess independent contributions. sCD40L values were logarithmically transformed before analysis. A P < 0.05 was regarded as significant. Analyses were performed using an SPSS software package (SPSS, Chicago, Illinois).
Echocardiogram. Echocardiogram was obtained according to

results
Median plasma sCD40L level was 8.7 ng/ml (interquartile range: 4.9-11.7). On the basis of sCD40L, patients were divided by tertiles (thresholds at 6.6 and 11.0 ng/ml). The three groups (Table 1) , the three groups were similar for eGFR, serum cystatin-C, AER, and distribution of microalbuminiuria. Consistently, sCD40L levels did not correlate with eGFR, cystatin-C, and log-transformed AER.
No differences were observed among the three groups in hs-CRP levels, and no correlation emerged between sCD40L and hs-CRP (r = 0.01, P = 0.93) ( Table 1) . Furthermore, while hs-CRP correlated with apolipoprotein B (r = 0.43, P < 0.001), fibrinogen (r = 0.62, P < 0.0001), and negatively with apolipoprotein A-I (r = -0.24, P < 0.05), sCD40L did not correlate with any of the above parameters.
Ambulatory BP values by tertiles of sCD40L levels are reported in Table 2 . Average 24-h systolic and diastolic, and also daytime and night-time BP levels were similar in the three groups. Frequency of nondippers was 47% in the first sCD40L levels tertile and 43% in the other tertiles.
The average IMT of the common carotid artery and percentage of subjects with wall thickening (IMT ≥0.9 to <1.3 mm) were superimposable in the three groups ( Table 3) . According to selection criteria, no patient had evidence of atherosclerotic plaque (IMT ≥1.3 mm). The carotid IMT was not correlated with circulating levels of sCD40L (r = 0.12, P = 0.20).
Concerning cardiac ultrasonographic parameters, LVMI, relative wall thickness, and both percentage of subjects with LVH and concentric pattern of LVH did not differ in the three groups ( Table 3) . Neither LVMI (r = 0.08, P = 0.25) nor relative wall thickness (r = 0.13, P = 0.12) were correlated with sCD40L levels.
β-Cell function did not differ between sCD40L tertiles (HOMA%B: 99 ± 35, 105 ± 46, and 109 ± 52, respectively). Area under the curve for both glucose (122 ± 30, 134 ± 38, and 139 ± 37 mg/min; P = 0.16) and insulin (61 ± 35, 77 ± 33, and 76 ± 34 µU/min, P = 0.27) showed an increase, although not significant, with sCD40L tertiles. A similar behavior emerged for basal insulin (11.2 ± 5.6, 14.7 ± 7.7, and 16.8±13.5 µU/ml, P = 0.10), while significant was the increase in fasting glucose (95 ± 11, 103 ± 16, and 105 ± 14 mg/dl, P = 0.028). As a result, percentage of subjects with impaired fasting glucose or impaired glucose tolerance increased from 33% in the first sCD40L tertile to 43 and 63% in the second and top tertile, respectively (χ 2 = 5.62; P = 0.06). Consistently, along with the increase in sCD40L, a worsening in insulin sensitivity was observed, which was expressed as HOMA%S (99 ± 52, 77 ± 43, and 72 ± 35, P < 0.05), ISIcomp (5.11 ± 2.65, 3.61 ± 1.98, and 3.28 ± 1.87, P = 0.025), or OGIS (421 ± 67, 386 ± 90, and 362 ± 72 mg/min/m 2 , P = 0.004). Finally, MFFM decreased along with the increase in sCD40L (6.88 ± 1.74, 5.86 ± 1.52, and 5.18 ± 1.46 units, P < 0.01) (Figure 1) .
By linear regression analyses, sCD40L levels correlated with fasting blood glucose (r = 0.27, P = 0.001), peak-glucose during OGTT (r = 0.24, P = 0.034), basal insulin (r = 0.34, P = 0.002), HOMA%S (r = −0.37, P = 0.001), ISIcomp (r = −0.28, P = 0.016), OGIS (r = −0.28, P = 0.014), and MFFM (r = −0.25, P = 0.027). To further define the relationship between each insulin resistance parameter, anthropometric measurements (BMI, waist), metabolic variables (fastingand peak-glucose during OGTT, LDL-and high-density lipoprotein-cholesterol, and triglycerides), eGFR and hs-CRP, stepwise regression analyses were performed with sCD40L as the dependent variable. These analyses yielded as many models in which only BMI adds independently to variability explained by basal insulin (multiple r = 0.44, P = 0.003), HOMA%S (multiple r = 0.49, P = 0.002), ISIcomp (multiple r = 0.38, P = 0.006), OGIS (multiple r = 0.40, P = 0.008), or MFFM (multiple r = 0.46, P = 0.003).
discussion
The cleaved form of membrane-bound CD40L, sCD40L, was found to be an independent biomarker for cardiovascular For all variables no statistically significant differences were detected by one-way analysis of variance, Kruskal-Wallis, or χ 2 -test. dBP, diastolic blood pressure; sBP, systolic blood pressure; sCD40L, soluble CD40 ligand.
articles sCD40L in Hypertension events with increased levels portending a worse prognosis. 24 Membrane-bound CD40L and sCD40L interaction with CD40 expressed on vascular cells results in inflammatory cytokines production and prothrombotic responses. Although still debated, elevated sCD40L levels have been described in subjects with hypertension, 13,16 a condition increasingly recognized as a low-grade inflammatory disorder. 25 In our study, sCD40L increases as insulin sensitivity decreases in nondiabetic men with newly diagnosed hypertension. sCD40L levels were associated both with HOMA%S and MFFM, estimating steady-state insulin sensitivity, as well as with nonsteady-state estimates (ISIcomp and OGIS) derived from a stimulatory model such as OGTT. 26 No correlations were observed with major cardiovascular risk factors, hs-CRP as a marker of low-grade inflammation, BP levels, left ventricular hypertrophy assessed by LVMI, microalbuminuria and renal function, or subclinical atherosclerosis assessed by carotid IMT.
Elevated sCD40L levels have been described in other clinical conditions characterized by insulin resistance, like type 2, but also type 1 diabetes. 3, 4 In type 2 diabetic patients, with or without cardiovascular disease, sCD40L failed to correlate with clinical parameters (age, BP, waist, or BMI), indices of metabolic control (lipid profile and HbA1c), or the degree of microalbuminuria. 4 However, in other studies a concurrent reduction of sCD40L levels with improvement of HbA1c was observed in type 2 diabetic subjects, 5, 6 though the variable extent of inhibition may suggest the involvement of other mechanisms possibly contributing to CD40L release, such as a thromboxane-dependent platelet activation. 5 Otherwise, the use of insulin-sensitizers such as the peroxisome proliferatoractivated receptor agonists troglitazone 3 and rosiglitazone 7 is associated with reductions in sCD40L in patients with diabetes.
Plasma sCD40L levels were higher in subjects with MS compared with those without MS, while no differences emerged, quite surprisingly, in fasting insulin. 8 Among the MS components, sCD40L was only related with abdominal obesity. 8 This finding, suggesting that obesity may promote CD40 overexpression, is consistent with others showing that sCD40L is elevated in obese subjects 27, 28 and with our observation of BMI, but not waist circumference, as a factor independently contributing to sCD40L levels in hypertensive men other than insulin sensitivity. In another study, sCD40L was inversely related to insulin sensitivity in obese women. 9 Also in this setting, pioglitazone improves insulin sensitivity and decreases sCD40L. 9 Some limitations of our study should be emphasized: the cross-sectional design and the relatively small sample size. Although this limitation might have reduced the power in detecting differences among measured variables, literature is not unanimous on the association of sCD40L with cardiovascular events, subclinical atherosclerosis or cardiovascular risk factors even when the largest studies are considered. 1, 2, 29 An additional limitation is that insulin sensitivity was only estimated and not directly measured. The glucose clamp remains the gold reference for insulin sensitivity assessment, but OGTT has recently received considerable interest, while HOMA and OGIS are considered to be solid proxies. 22 A further limitation is the lack of extent to the female gender. However, restriction to men was aimed to recruit a population as more homogeneous as possible (female sex has been positively related to plasma sCD40L) 29 and at relatively higher cardiovascular risk.
sCD40L levels observed in our study look quite higher than those reported in some paper, 16, 18 though not different from those reported by others. 13 We have no convincing explanation for such variable findings among patients with hypertension. Procedures of sample acquisition are critical determinants of CD40L concentration that shows a time-dependent increase if samples are kept at room temperature. 29 In our study, in agreement with others, 16 samples have been kept on ice, and than frozen and stored at −70 °C until determination, by thawing them just once.
It has been suggested that increased sCD40L might discriminate among hypertensive patients, those at high cardiovascular risk. 25 To this regard, several observations are of interest.
It was shown that sCD40L levels did not differ in subjects stratified by grades of hypertension. 13 Confirming this finding, in our study both clinic and 24-h BP were similar throughout sCD40L tertiles. Thus, sCD40L fails to discriminate increased risk imposed per se by higher BP levels.
Increased sCD40L levels have been described in nevertreated hypertensive patients with blunted nocturnal BP decrease, a condition associated with greater target organ damage. 16 However, in our study, also conducted in never-treated but only male subjects, night-time BP values and prevalence of nondippers did not differ among sCD40L tertiles.
LVH is a marker of hypertension-related target organ damage, and a strong and independent risk factor for cardiovascular outcomes, 30 so that risk increases with increasing LVM. In this study, LVMI does not correlate with sCD40L and percentage of subjects with LVH does not change with increasing sCD40L. sCD40L levels appear to discriminate a subset of hypertensive patients characterized by microalbuminuria and low-grade inflammation. 18 Microalbuminuria accompanied by subclinical inflammation is a strong correlate of metabolic abnormalities in hypertension, and identifies a subset at very high cardiovascular risk. 31 However, in this study, AER, percentage of microalbuminuric subjects, as well hs-CRP and fibrinogen were superimposable through sCD40L tertiles. Furthermore, eGFR and cystatin-C did not differ among sCD40L tertiles. Consistently, microalbuminuria was not accompanied by an increase in sCD40L in nonobese, nonsmoking hypertensive men. 32 Thus, in our study, sCD40L fails in discriminating increased risk associated with impairment in dipping BP, occurrence of LVH or coexistence of microalbuminuria (both conditions being related to the duration of hypertension) as well with low-grade inflammation.
In conclusion, our findings support the hypothesis that reduced insulin sensitivity and its associated hyperinsulinemia, and not other cardiovascular risk factors or the degree of subclinical atherosclerosis, are major determinants of enhanced platelet activation and CD40L release in the setting of newly diagnosed hypertension, with a minor but independent role played by body weight. This is consistent with a recent report, where only insulin sensitivity and higher waist were associated with increased plasma sCD40L in nondiabetic dyslipidemic patients, 33 therefore suggesting that sCD40L might discriminate among hypertensive (and dyslipidemic) subjects those at higher cardiovascular risk due to the coexistence of impaired insulin sensitivity. 34 Disclosure: the authors declared no conflict of interest.
